Zydus to Acquire US Oncology Pharma Firm Assertio in USD 166 Million Deal

As part of the transaction, Zydus will acquire all outstanding shares of Assertio at USD 23.50 per share through its wholly owned acquisition subsidiary, Zara Merger Sub Inc. The deal has already received approval from the boards of both companies and will be completed through a tender offer followed by a merger, subject to regulatory clearances and customary closing conditions.

Assertio is a Nasdaq-listed specialty pharmaceutical company focused on oncology supportive-care therapies in the United States. The company markets Rolvedon (eflapegrastim-xnst), a long-acting G-CSF biologic approved by the USFDA for preventing febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. The treatment is administered once during every chemotherapy cycle.

Through this acquisition, Zydus aims to strengthen its specialty oncology presence in the US market by leveraging Assertio’s established commercial infrastructure, including its network of more than 170 community oncology accounts and buy-and-bill capabilities.

According to the Zydus Lifesciences press release, the acquisition is expected to close in the financial year 2026-27 and Assertio will subsequently be delisted from Nasdaq.

Commenting on the development, Dr Sharvil P Patel, Managing Director of Zydus Lifesciences, said the acquisition represents a strategic step towards expanding the company’s specialty and oncology footprint globally while building differentiated specialty businesses in regulated markets.